A small capsule could change how we study the microbiome of the small intestine. A team led by researchers at the University of Tokyo has created a pill-shaped device designed to take samples from the small intestine using a tiny extendable brush.
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose bladder cancer more accurately than current standard methods. The test also allows physicians not only to assess the cancer’s response to treatment but also to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.
The spread of cancer from a primary tumor to another place in the body, called metastasis, remains one of the greatest challenges in cancer treatment and is responsible for most cancer-related deaths.
Wristband device from Encora Therapeutics started as a project in 2.009, MIT’s iconic product-design class.
Mendaera announced its handheld robot for needle-based procedures is now available to pair with Butterfly Network’s (NYSE:BFLY) portable, chip-based ultrasound probe, following the companies’ long-running collaboration.
A new study led by researchers from the Icahn School of Medicine at Mount Sinai and published in Brain Communications found that a transcranial low-amplitude magnetic field intervention delivered twice weekly into the brain through a noninvasive headset was associated with improvements in several measures of cognitive function and emotional well-being in people experiencing cognitive impairment associated with long COVID.
Researchers have developed 3D “mini-brains” they hope will help speed up the search for much-needed drug treatments for multiple sclerosis (MS), an autoimmune condition affecting almost 3 million people worldwide. Their research has been published in the journal Nature Neuroscience.
Scientists at the Montreal Clinical Research Institute (IRCM), led by Université de Montréal medical professor Javier Di Noia, have shed light on a fundamental mystery in immunology: How do immune cells manage to concentrate a powerful mutagenic enzyme at precisely defined regions of DNA while largely sparing the rest of the genome from potentially dangerous damage?
MARLBOROUGH, Mass., Oct. 1, 2026 /PRNewswire/ — BTL Industries, a global leader in medical and wellness technologies, today announced expanded FDA clearances for EXOMIND®, its noninvasive brain stimulation platform.
Medtronic plans to study the device in patients with peripheral artery disease below the knee, a historically difficult condition to treat.